EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06401421

Contact name

Laura Morse Cucci

Clinical trials study type

Oncology - Breast

Clinical trials trial status

Open to Accrual

IRB number

2213466

Principal investigator

Robert Donegan, MD

Clinical trials study number

NSABP-B64 | EXActDNA-003 (G2402)

Phone

443-849-3122

Clinical trials title (full)

EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)